Collegium Pharmaceutical Inc (COLL) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Total Assets Chart for Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc (COLL) total assets for FY2025 were USD 1.7B, a -0.4% change from FY2024. Collegium Pharmaceutical Inc's total assets grew from USD 9.0M in 2013 to USD 1.7B in 2025 (18240.0% over 12 years). Total assets compound annual growth rate: 5-year CAGR of 20.8%, 10-year CAGR of 32.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $747.48M
- Implied Share Price
- $22.96
- Enterprise Value
- $1.70B
- Revenue (TTM)
- $808.21M
- EBITDA
- $405.26M
- Profit Margin
- 5.93%
- Trailing P/E
- 18.08
- Forward P/E
- 4.79
- Price/Book (MRQ)
- 4.65
- Price/Sales (TTM)
- 0.92
- EV/EBITDA
- 4.87
- EV/Revenue
- 2.39
- Dividend Yield
- —
- Book Value
- $9.60
- Free Cash Flow (FY2025)
- $327.58M
- Free Cash Flow Yield
- 43.83%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.